Disclosed in a recent SEC filing on April 17, Collis, Chairman at Cencora (NYSE:COR), made a noteworthy transaction involving the exercise of company stock options.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday revealed that Collis, Chairman at Cencora in the Health Care sector, exercised stock options for 10,754 shares of COR stock. The exercise price of the options was $89.58 per share.
The Thursday morning update indicates Cencora shares down by 0.17%, currently priced at $238.22. At this value, Collis's 10,754 shares are worth $1,598,528.
Unveiling the Story Behind Cencora
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora's Financial Performance
Revenue Growth: Over the 3 months period, Cencora showcased positive performance, achieving a revenue growth rate ...